stockportfolio.pro
Stocks / MRNA vs ROIV
MRNA vs ROIV
Moderna, Inc. and Roivant Sciences Ltd. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Moderna, Inc. (MRNA) | Roivant Sciences Ltd. (ROIV) | |
|---|---|---|
| Market cap | $18.9B | $20.5B |
| Revenue (latest FY) | $1.94B | $8.26M |
| Net income (latest FY) | $-2.82B | $-299.77M |
| Revenue growth (5y CAGR) | 19.3% | -19.1% |
| Net margin | -145.2% | -3629.2% |
| Return on equity | -32.6% | -6.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 2 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open MRNA — free Open ROIV — freeFrequently asked questions
Which is bigger, MRNA or ROIV?
Roivant Sciences Ltd. is larger by market capitalization — $20.5B versus $18.9B.
Which grows faster, MRNA or ROIV?
Over the last five fiscal years, Moderna, Inc. grew revenue faster — 19.3%/yr versus -19.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.